The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.
Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.
Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after
1. curative-intended surgery and
2. adjuvant chemotherapy.
FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
* Age 18 years or older.
* Scheduled for curative intent surgical resection.
Exclusion Criteria:
* Hereditary pancreatic cancer.
* Verified distant metastases.
* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
* Pregnant or nursing woman, or in childbearing age and not willing to use contraception
* Adult subject to a legal protection
* Not covered by Health insurance
* Patient unable to understand and sign written informed consent.
Primary outcome measure(s)
3-year Disease-free survival (DFS) — 3 years after the end of inclusion Disease-free survival was defined as the time between the date of the baseline blood sampling/inclusion and the date of the first event among or recurrence or death from any cause.
Trial sites (1)
Facility
City
Region
Status
CHU de Montpellier
Montpellier
Hérault
Recruiting
More University Hospital, Montpellier trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
